Tamoxifen pharmacogenetics moves closer to reality.
Garber
Ken
K
D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology; D018931:Antineoplastic Agents, Hormonal / Q000493:pharmacokinetics; D047072:Aromatase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000009:adverse effects / Q000493:pharmacokinetics*; D005838:Genotype; D019584:Hot Flashes / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D017374:Paroxetine / Q000494:pharmacology* / Q000627:therapeutic use; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011237:Predictive Value of Tests; D013629:Tamoxifen / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000494:pharmacology
D018687:Antidepressive Agents, Second-Generation; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004791:Enzyme Inhibitors; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen; C016601:afimoxifene; D017374:Paroxetine; D019389:Cytochrome P-450 CYP2D6